 | Info
Sheets |
| | | | | | | | | | | | | | | | | | | | | | |
 | Out-
side |
| | | | |
|
| | | | |
Result : Searchterm 'Resovist' found in 1 term [ ] and 5 definitions [ ]
| | 1 - 5 (of 6) nextResult Pages : [1] [2] | |  | |
 |
Searchterm 'Resovist'
was also found in the following service of MR-TIP.com: |
|
| | | | |  |
| Resovist® |   |
| |
|
Resovist® is an organ-specific MRI contrast agent, used for the detection and characterization of especially small focal liver lesions.
Resovist® consists of superparamagnetic iron oxide (SPIO) nanoparticles coated with carboxydextran, which are accumulated by phagocytosis in cells of the reticuloendothelial system (RES) of the liver. The uptake of Resovist® Injection in the reticuloendothelial cells results in a decrease of the signal intensity of normal liver parenchyma on both T2- and T1 weighted images.
Most malignant liver tumors do not contain RES cells and therefore do not uptake the iron particles. The resulting imaging effect is an improved contrast between the tumor (bright) and the surrounding tissue (dark).
Resovist® is injected as an intravenous bolus, allows immediate imaging of the liver, and therefore reduces the overall examination time. A dynamic imaging strategy after bolus injection allow to characterize lesions.
In comprehensive clinical trials, it demonstrated an excellent safety profile.
In 2001, Resovist® was approved for the European market.
See also Superparamagnetic Iron Oxide.
|
|
Drug Information and Specification |
| NAME OF COMPOUND |
Ferrixan [Ferucarbotran], carboxydextran coated iron oxide nanoparticles
|
| DEVELOPER |
Bayer Schering Pharma AG
|
| CENTRAL MOIETY |
Fe2+ |
| CONTRAST EFFECT |
T2/T1, Predominantly negative enhancement |
| RELAXIVITY |
r1=25.4, r2=151, |
| PHARMACOKINETIC |
RES-directed |
| OSMOLALITY |
333 mosm/kg |
| CONCENTRATION |
0.5 mol Fe/L |
| DOSAGE |
Less than 60 kg = 0.9 ml, greater than 60 kg = 1.4 ml |
| PREPARATION |
Finished product |
| INDICATION |
Liver lesions |
| DEVELOPMENT STAGE |
Phase III in USA
For sale in Europe, Australia and Japan |
| DISTRIBUTOR |
See below |
| PRESENTATION |
Pre-filled syringes of 0.9 and 1.4 mL |
| DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING
PACKAGE INSERT! |
|
|
| | | |
 Further Reading: |
Basics:
|
|
News & More:
| | | | |
| |
 |
MRI Resources |
|
| | | | | | | |
|
Searchterm 'Resovist'
was also found in the following service of MR-TIP.com: |
|
| | | |
|
|  |
| Ferucarbotran | |
| |
|
| | | |
| Further Reading: |
News & More:
|
| | |
| |
|
MRI Resources |
|
| | | | | | |
| Bayer Schering Pharma AG | |
| |
|
The Germany-based pharmaceutical company is the result of the take-over of Schering AG by Bayer AG in 2006. The Bayer Schering Pharma AG is part of the Bayer HealthCare AG, which represents the pharmaceutical part of the Bayer Group. Activities of the Bayer Schering Pharma AG are Diagnostic Imaging, Hematology & Cardiology, Oncology, Primary Care, Specialized Therapeutics and Women's Healthcare. The diagnostic imaging part's contrast agents for MRI, x-ray and CT are 'world-market leaders'.
|
| |
|
| | | |
| Further Reading: |
Basics:
|
|
News & More:
| | | | | •• There are 25 news about 'Bayer Schering Pharma AG'. | |
| |
|
Searchterm 'Resovist'
was also found in the following service of MR-TIP.com: |
|
| | | |
|
| |
| SHU 555 C | |
| |
|
| | | |
| Further Reading: |
Basics:
|
|
News & More:
| | | |
| |
|
|
MRI Resources |
|
| | | | | | | 1 - 5 (of 6) nextResult Pages : [1] [2] |
| |
|
| |
 | Look
Ups |
| |
bottom
(.pdf)
Random Page
top